There is currently no cure for allergies. Over-the-counter and prescription medications relieve patients of symptoms, but don’t prevent allergy from progressing. The only disease-modifying treatment against allergy is desensitization, a form of allergen immunotherapy (AIT). Patients receive allergy shots in the form of weekly then monthly injections or daily sublingual tablets or drops. Aluminum salt-based adjuvants are used for subcutaneous administration. But the treatment needs to continue for 3 to 5 years for sustained efficacy, and throughout the course of the treatment, side effects like throat swelling, wheezing, and chest tightness are common.
For leading Franco-Canadian biotech company ANGANY, it all started with allergy. It has found a novel way to overcome the drawbacks of these existing allergy treatments.
Leveraging 30 years of R&D in biotechnology, immunology, and vaccinology, ANGANY has developed a biosynthetic allergen-lipid ultrastructure, called an eBioparticle™, which effectively turns natural allergens into larger 3D structures that resemble viruses.
eBioparticles mimic viral pathogens in shape, dimension, and surface antigenic motif. They resemble the complex molecular structure of a virus, but do not contain any of its infectious genetic material or viral immunogenic patients’ allergy dynamics, particularly in children, may well be ANGANY’s best shot at reversing the epidemiology of allergy and the past decades of ever worsening statistics.